Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4790682 | 0.78 | NPC1 (0.47) | ALDH1A1MAPTNAMPTNPC1RAB9A | |
| SCHEMBL4789373 | 0.78 | DPP4 (0.48) | ALDH1A1TAAR1KDM4E | |
| SCHEMBL4790954 | 0.78 | NAMPT (0.47) | NAMPT | |
| SCHEMBL1470470 | 0.76 | MTNR1A (0.50) | ALDH1A1 | |
| SCHEMBL4789524 | 0.75 | RAB9A (0.59) | ALDH1A1MAPTNAMPTNPC1RAB9A | |
| SCHEMBL4791121 | 0.75 | CACNA1G (0.47) | TDP1NAMPTCACNA1G | |
| SCHEMBL4714941 | 0.73 | GRIN2B (0.39) | NAMPT | |
| SCHEMBL4760965 | 0.73 | NAMPT (0.45) | NAMPT | |
| SCHEMBL15715850 | 0.72 | MTNR1A (0.49) | — | |
| SCHEMBL4715261 | 0.71 | NAMPT (0.40) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |